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Abstract The purpose of this study was to evaluate whether or 
not, using sensitive analytical methods for the 
measurement of coagulation and fibrinolysis enzyme 
activity, there was a hypercoagulable state in patients 
with melanoma, and whether differences existed between 
those with or without metastases. Seventy-one patients 
were studied, 45 with localized tumors (stages Ia and 
Ib) and 26 with metastases (stages II-IV). Plasma level 
of activated factor VII, prothrombin fragment 1+2, 
thrombin-antithrombin complex, fibrinopeptide A, 
plasmin-antiplasmin complex and D-dimer were much higher 
in the whole group of 71 patients than in 45 controls 
with benign nevi. However, when melanoma patients with 
or without metastases were compared, there were smaller 
differences, with only thrombin-antithrombin complex, 
plasmin-antiplasmin and D-dimer significantly higher in 
metastatic melanoma. These results indicate that in 
patients carrying a tumor endowed with high procoagulant 
activity in vitro, there is a laboratory picture of 
hypercoagulability with secondary hyperfibrinolysis in 
vivo -- However, differences between patients with 
localized and metastatic tumors for markers of 
hypercoagulability are not striking, in spite of the 
fact that metastatic cells support greater coagulant 
activity than primary cells in vitro. 
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Malignant melanoma is a tumor of neuroectodermic origin 
endowed with peculiar effects on blood coagulation. Studying 
extracts of primary tumor cells obtained at biopsy or surgery, 
Gambacorta-Passerini et al.[l] identified a procoagulant activity 
with the functional characteristics of an activator of factor X. 
Further biochemical and immunological studies demonstrated that 
the factor X activator from melanoma cells is a cysteine protease 
[1,2], whereas benign melanocytic nevi studied as controls were 
devoid of such enzymatic activity [l]. It was also observed that 
cellular extracts from metastatic lesions were at least four 
times more enzymatically active than primary lesions [ll. 
Melanoma-derived cell lines also expressed tissue factor-like 
activity 131. 
A few years ago, these findings prompted us to characterize 
in vivo the coagulation status of patients with melanoma, 
precisely staged for tumor localization or dissemination [4]. We 
found rather modest alterations of the parameters chosen for that 
study, such as mild increases of factors V and VIII in plasma and 
high serum levels of fibrinogen-fibrin degradation products [41. 
Such alterations were not strikingly greater in patients with 
metastatic melanoma than in those with localized tumors, in 
contrast with marked differences in procoagulant activities 
found in vitro [l]. 
Our incapacity to differentiate localized from metastatic 
melanoma by coagulation measurements might be due to the 
insensitivity of the tests chosen. The measurement of the plasma 
levels of coagulation zymogens, proactivators and regulatory 
proteins [4] is perhaps unable to reveal the subtle changes of 
coagulation enzyme activity induced by procoagulant moieties from 
melanoma cells. In the past few years, more sensitive analytical 
methods became available, such as those that measure directly or 
indirectly active enzymes in the coagulation and fibrinolytic 
systems [51. This methodological progress prompted us to 
reinvestigate whether or not, using such highly sensitive 
markers, it would be possible to demonstrate more clearly 
hypercoagulability in patients with melanoma, and whether 
hypercoagulability was more marked in patients with metastatic 
disease. 
MATERIALS AND METHODS 
Patients and controls. Seventy-one patients with melanoma, 
referred consecutively to the National Cancer Institute of Milan, 
consisted of 45 patients without metastases (18 women and 27 men, 
median age 51 years, range 16-78) and 26 patients (16 women and 
10 men, median age 55 years, range 29-81) with metastases (stages 
II, III or IV). The tumor stage was established according to 
previously described criteria [41. Histological diagnosis was 
verified in all cases after surgery. Controls consisted of 45 
individuals (18 women and 27 men, median age 50 years, range 14- 
79) with benign melanocytic nevi. Previous or current 
thromboembolic disorders, anticoagulant and hormonal therapy and 
surgery in the last ten days were criteria for exclusion from the 
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Blood collection and plasma preparation. Blood collection 
was performed by venipuncture using a 19 G needle connected to an 
outlet into siliconized glass vacuum tubes. The first tube was 
discarded; the next (containing citrate, heoarin and aprotinin in 
unknown concentrations) was used for fibrinopeptide A assay and 
was supplied by the kit manufacturer (see below); for the 
remaining coagulation assays blood was collected into tubes 
containing l/10 volume of 3.8% trisodium citrate. After filling, 
tubes were mixed by inverting them several times and placed in 
melting ice, except that used for measuring activated factor VII. 
Blood was centrifuged within 60 min of collection at 4OC for 20 
min at 2000 x g, aliquots of plasma were snap-frozen and stored 
at -80° C until tested within two months. 
Methods. Fibrinopeotide A, an index of fibrin formation 
from fibrinogen, was measured by ELISA in plasma extracted twice 
with bentonite to remove fibrinogen (Diagnostica Stago, Asnieres, 
France). Prothrombin fragment 1 + 2 (an index of activated factor 
X activity on prothrombin), thrombin-antithrombin complex (an 
index of thrombin formation), plasmin-antiolasmin complex (an 
index of plasmin formation) and D-dimer (an index of lysis of 
cross-linked fibrin) were measured by ELISAs (Enzygnost Fl+2, TAT 
and PAP, Behringwerke, Marburg, Germany; and Dimertest, Agen, 
Biomedical, Brisbane,Australia) . Activated factor VII (factor 
VIIa, the enzymatic form of factor VII), was measured by a one- 
stage, prothrombin time-based assay using a truncated soluble 
form of recombinant tissue factor (kindly supplied by Dr. Y. 
Nemerson, Mount Sinai Hospital Medical School, New York, NY), 
that upon relipidation reacts with factor VIIa but not with 
factor VII zymogen [6]. 
Statistical analysis. Since the values of coagulation 
markers were not normally distributed, logarithmic transformation 
was carried out and normalization was obtained. Descriptive 
statistics include geometric means and 95% confidence limits. 
Linear correlation coefficients (r values) were also calculated. 
P values lower than 0.05 were regarded as statistically 
significant. 
RESULTS 
We first compared all the 71 melanoma patients, whether or 
not they had metastatic disease, with the controls with nevi. 
There were differences between controls and patients, who had a 
laboratory picture reflecting heightened coagulation and 
fibrinolysis enzyme activity (Table 1). Factor VIIa was 
significantly increased; there were also signs of enhanced 
thrombin generation (expressed by high plasma levels of 
prothrombin fragment 1+2 and thrombin-antithrombin complex); of 
fibrin formation, expressed by high levels of fibrinopeptide A 
and of plasmin activity, expressed by high levels of D-dimer and 
plasmin-antiplasmin complex (Table 1). However, when melanoma 
patients with and without metastases were compared, there was 
little difference in the plasma levels of coagulation activation 
markers, 
11, 
with only thrombin-antithrombin complex (P= 0.01) (Fig. 
D-dimer (P<O.OOl) (Fia. 2) and plasmin-antiplasmin complex 
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(P= 0.001) (Fig. 3) higher in metastatic melanoma. Table 2 shows 
the correlation coefficients of the activation markers. 
TABLE 1 
Markers of the coagulation enzyme activity in patients 
with melanoma and in controls with melanocytic nevi 
neasurements nelanocytic All Localized Uetastatic p values 
nevi melanamas melanomas melanomas lZ2 3&%4 
stage I stage II-Iv 
(1) (2) (3) 14) 
Activated factor VII 
IWIIal nglml 
2.90 
(2.61-3.24) 
3.63 
(3.36-3.93) 
3.52 
(3.16-3.93) 
3.84 
13.43-4.29) 0.0008 N.S. 
0.0008 N.S. 
Protbrcabin 
fragment 1+2 lF1+21. 
"mOl/L 
1.24 
(1.08-1.42) 
0.92 
(0.83-1.01) 
1.16 1.11 
(1.06-1.26) (0.99-1.24) 
Thrombin/antithrombin 
complex (TAT), "g/ml 
2.45 
(2.22-2.72) 
3.03 
(2.62-3.51) 
2.65 
(2.23-3.16) 
3.84 
(3.01-4.891 0.034 0.01 
0.0003 N.S. 
0.0017 0.0001 
0.018 0.001 
Fibrinopeptide A (PPAI 
"mOl/L 
0.90 1.20 
(0.81-1.00) (1.08-1.321 
1.19 
(1.04-1.35) 
1.21 
(1.01-1.451 
D-Dim3 ID-D), 
"g/ml 
41 
(35-47) 
71 
155-91) 
47 142 
(36-621 (94-2151 
Plasmin-antiplasmin 
complex (PAP), "g/ml 
331 
(301-365) 
393 
(357-4331 
338 511 
(312-366) (422-6151 
Values are given as gezxretric means and, between parenthesis, 95 per cent confidence intervals 
TABLE 2 
Correlation coefficients (r values) between markers of coagulation 
and fibrinolysis enzyme activity in all patients with melan-a. 
WIIa 0.35. 0.03 0.21 0.21+ 0.15 
F1+2 0.11 0.54* 0.51* 0.25 
PPA 0.36* 0.30* 0.44. 
l 
TAT 0.71 0.55' 
l P < 0.05 
* P < 0.01 
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Figure 1. Plasma concentrations of thrombin-antithrombin complex 
in patients with melanocytic nevi (solid circles), 
localized melanoma (open circles) and metastatic 
melanoma (striped circles). The horizontal lines denote 
the geometric mean value of each parameter in each 
group. 
DISCUSSION 
The sensitive direct or indirect markers of coagulation and 
fibrinolysis enzyme activity employed in this study document the 
existence of a laboratory state of hypercoagulability and 
hyperfibrinolysis in several melanoma patients. However, patients 
with and without metastases could not be clearly distinguished. 
According to the in vitro characterization of the procoagulant 
activities of primary and metastatic melanoma cells [l], the 
latters should activate coagulation to a greater degree. Only D- 
dimer, an index of intravascular or extravascular fibrin 
formation and lysis, and, to a lesser extent, thrombin- 
antithrombin and plasmin-antiplasmin complexes, indexes of 
heightened thrombin formation and fibrinolysis, were 
significantly higher in patients with metastases than in those 
without. 
350 HYPERCOAGUABILITY IN MELANOMA Vol. 81, No. 3 
Hypercoagulability appeared to be mainly triggered by the 
activation of the tissue factor pathway, as shown by high levels 
of factor VIIa, the key enzyme generated in the pathway by tissue 
factor-factor VII-factor VIIa interactions [71. The elevation of 
factor VIIa, the principal physiological activator of factor X, 
would mechanistically explain why factor Xa activity is high, 
resulting in turn in a greater cleavage of prothrombin and 
increased formation of the fragment 1+2. Heightened prothrombin 
activation would then lead to greater thrombin generation 
(reflected by high levels of thrombin-antithrombin complex), 
fibrin formation (high fibrinopeptide A) and secondary 
fibrinolysis (high D-dimer and plasmin-antiplasmin complex). The 
values of the markers of coagulation activation were in general 
correlated with those of hyperfibrinolysis, supporting the views 
that they are associated phenomena. 
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Figure 2 . Plasma concentrations of D-dimer. See Fig. 1 for 
symbols. 
The mechanisms underlying the activation of factor VII are 
still speculative. Activation may be mediated by the exposure on 
melanoma cells of tissue factor, a feature common to many tumor 
cells [8J. Factor VIIa may also be generated on tissue factor 
exposed on monocytes or other cells activated by the malignant 
cells [9, 101. Since no increase was found in markers of 
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coagulation enzyme activity as tumor burden increased, it is hard 
to imagine that factor VII activation is engendered by the 
tumor, which may suggest that perhaps it is from monocytes or 
other tumor activated cells. Finally, elevations of markers may 
also be triggered by the peculiar factor X activator expressed 
by melanoma cells [l, 21. 
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Figure 3. Plasma concentration of plasmin-antiplasmin complex. 
See Fig. 1 for symbols. 
In conclusion, this study has characterized with sensitive 
markers of enzyme activity the coagulation and fibrinolysis 
status of patients with melanoma. A hypercoagulable state exists 
in the majority of these patients, even in the early stages of 
the disease without metastases, leading to fibrin formation and 
secondary fibrinolysis. The pathophysiological significance of 
the alterations remains to be established. The hypercoagulable 
state may facilitate the tendency of these patients to develop 
thromboembolic complications. Perhaps increased fibrin formation 
may also provide a network that would facilitate dissemination of 
melanoma cells from the primary tumor and enhance metastases 
formation, but this remains to be established with clinical 
trials of anticoagulants agents. 
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